Hubert Tissot1, Véronique Roch2, Olivier Morel3, Nicolas Veran4, Mathieu Perrin4, Marine Claudin4, Antoine Verger1,5, Gilles Karcher1, Pierre-Yves Marie1,6, Laetitia Imbert7,8,9. 1. Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France. 2. Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France. 3. CHU-Besançon, Université de Franche-Comté, Service de Médecine Nucléaire, 25000, Besançon, France. 4. Department of Nuclear Medicine, CHRU-Nancy, 54000, Nancy, France. 5. INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France. 6. INSERM, UMR 1116, Université de Lorraine, 54000, Nancy, France. 7. Department of Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, 54000, Nancy, France. l.imbert@chu-nancy.fr. 8. INSERM, UMR 1254, Université de Lorraine, 54000, Nancy, France. l.imbert@chu-nancy.fr. 9. Médecine Nucléaire, Hôpital de Brabois, CHRU-Nancy, Allée du Morvan, 54500, Vandoeuvre-Les-Nancy, France. l.imbert@chu-nancy.fr.
Abstract
PURPOSE: To determine whether the left ventricular ejection fractions (EFs), measured on a high-sensitivity CZT single photon emission computed tomography (SPECT)-camera with a 70% reduction in recording times and a prevention of EF overestimation through an additional count-calibration, are concordant with reference EF from planar radionuclide angiography (2D-RNA). METHODS: An additional 10-minute CZT-SPECT recording was performed in patients referred to 2D-RNA for cardiomyopathy (n = 23) or chemotherapy monitoring (n = 50) with an in vivo red blood cell labeling with 850 MBq [Formula: see text]. The EF, obtained from CZT-SPECT with 100% (SPECT100) or 30% (SPECT30) projection times and with a SPECT-count calibration on the 2D-RNA counts of corresponding cavity volumes, were compared to EF from 2D-RNA. RESULTS: Strong and equivalent relationships were documented between the EF from 2D-RNA and the calibrated EF from SPECT100 (y = 0.89x + 6.62; R2 = 0.87) and SPECT30 (y = 0.87x + 8.40; R2 = 0.85), and the mean EF from SPECT100 (54% ± 15%) and SPECT30 (53% ± 16%) were close to that from 2D-RNA (55% ± 15%). However, upward shifts in these mean values were documented in the absence of count calibration for both SPECT100 (60% ± 18%) and SPECT30 (60% ± 18%). CONCLUSION: Left ventricular EF may be determined on a high-sensitivity CZT-camera, a 70% reduction in injected activities, and an additional count-calibration for further enhancing the concordance with 2D-RNA values.
PURPOSE: To determine whether the left ventricular ejection fractions (EFs), measured on a high-sensitivity CZT single photon emission computed tomography (SPECT)-camera with a 70% reduction in recording times and a prevention of EF overestimation through an additional count-calibration, are concordant with reference EF from planar radionuclide angiography (2D-RNA). METHODS: An additional 10-minute CZT-SPECT recording was performed in patients referred to 2D-RNA for cardiomyopathy (n = 23) or chemotherapy monitoring (n = 50) with an in vivo red blood cell labeling with 850 MBq [Formula: see text]. The EF, obtained from CZT-SPECT with 100% (SPECT100) or 30% (SPECT30) projection times and with a SPECT-count calibration on the 2D-RNA counts of corresponding cavity volumes, were compared to EF from 2D-RNA. RESULTS: Strong and equivalent relationships were documented between the EF from 2D-RNA and the calibrated EF from SPECT100 (y = 0.89x + 6.62; R2 = 0.87) and SPECT30 (y = 0.87x + 8.40; R2 = 0.85), and the mean EF from SPECT100 (54% ± 15%) and SPECT30 (53% ± 16%) were close to that from 2D-RNA (55% ± 15%). However, upward shifts in these mean values were documented in the absence of count calibration for both SPECT100 (60% ± 18%) and SPECT30 (60% ± 18%). CONCLUSION: Left ventricular EF may be determined on a high-sensitivity CZT-camera, a 70% reduction in injected activities, and an additional count-calibration for further enhancing the concordance with 2D-RNA values.
Authors: François Harel; Vincent Finnerty; Jean Grégoire; Bernard Thibault; François Marcotte; Patricia Ugolini; Paul Khairy Journal: J Nucl Cardiol Date: 2010-02-12 Impact factor: 5.952
Authors: G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Riemer H J A Slart; René A Tio; Clark J Zeebregts; Antoon T M Willemsen; Rudi A J O Dierckx; Johan De Sutter Journal: Ann Nucl Med Date: 2008-05-23 Impact factor: 2.668